Centauri Therapeutics
Related Articles
Centauri extends Series A to £30M with AMR Action Fund
Centauri Therapeutics has extended its Series A to £30M, including a £6M investment from the AMR Action Fund, to support Phase I progress for lead candidate CTX-187.
AMR Action Fund backs Centauri with EUR 23.62m
Centauri Therapeutics has announced a EUR 23.62 million funding from the AMR Action Fund to advance its Alphamer-based “programmable immunity” approach targeting antimicrobial resistance.